Skip to content
  • Monday, 17 August 2026
  • 3:08 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • J&J Positions Spravato Remission Data at Forefront of Treatment-Resistant Depression Growth Strategy
Laboratory Automation & Robotics

J&J Positions Spravato Remission Data at Forefront of Treatment-Resistant Depression Growth Strategy

Lana Keisha Jul 12, 2026 0

Johnson & Johnson (J&J) is intensifying its marketing efforts for Spravato (esketamine) by spotlighting compelling remission rate data for treatment-resistant…

Read More
Pharmaceutical R&D

Bocunebart’s PACAP-Targeting Mechanism Positions it as a Potential First-in-Class Therapy in a Thin Pipeline of Novel Late-Stage Candidates

Teuku Ryan Jul 2, 2026 0

New Data Unveiled for Bocunebart, a Promising Migraine Preventive Targeting a Novel Pathway Munich, Germany – June 29, 2026 –…

Read More
ADA Conference Highlights: GLP-1 Innovations Reshape Metabolic Treatment Landscape Amidst Unprecedented Scientific Advocacy ProtestThis crocodile ran like a greyhound across prehistoric Britain 200 million years agoSelf-Organizing Optical Tornadoes: Breakthrough in Liquid Crystal Photonics Enables Stable Ground-State Light Vortices for Quantum CommunicationScience News: A Century of Empowering Public Understanding of Science
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ